Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Therapy01:28

Drug Therapy

114
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
114
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

COVID-19 vaccines and multiple sclerosis disease-modifying therapies.

Multiple sclerosis and related disorders·2021
Same author

Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis.

Multiple sclerosis journal - experimental, translational and clinical·2021
Same author

Evaluation of remote assessments for multiple sclerosis in an in-home setting.

Multiple sclerosis and related disorders·2021
Same author

Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement.

Journal of neuroimmunology·2021
Same author

Probing the association between Multiple Sclerosis and Epstein Barr Virus from a therapeutic perspective.

Multiple sclerosis and related disorders·2021
Same author

Can rheumatologists stop causing demyelinating disease?

Multiple sclerosis and related disorders·2021

Related Experiment Video

Updated: Oct 10, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

Derisking CD20-therapies for long-term use.

Ide Smets1, Gavin Giovannoni1

  • 1Blizard Institute, Centre for Neuroscience, Surgery and Trauma, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, 4 Newark St, Whitechapel, London E1 2AT, United Kingdom; Clinical Board Medicine (Neuroscience), Royal London Hospital, Barts Health NHS Trust, Whitechapel Road, London E1 1FR, United Kingdom.

Multiple Sclerosis and Related Disorders
|December 13, 2021
PubMed
Summary

This review outlines six key steps to safely use anti-CD20 therapies for neuroinflammatory conditions like multiple sclerosis (MS). Strategies include screening, vaccinations, family planning, managing side effects, and optimizing dosing for better risk-benefit balance.

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.4K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

866

Related Experiment Videos

Last Updated: Oct 10, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.4K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

866

Area of Science:

  • Neuroimmunology
  • Pharmacology

Background:

  • Anti-CD20 therapies are crucial for treating multiple sclerosis (MS) and other neuroinflammatory diseases.
  • The risk-benefit profile of anti-CD20 agents shifts during maintenance therapy.

Purpose of the Study:

  • To propose a structured, six-step approach to mitigate risks associated with anti-CD20 therapies.
  • To enhance the safety and efficacy of long-term anti-CD20 treatment in neuroinflammatory conditions.

Main Methods:

  • Review of current literature and clinical practices regarding anti-CD20 therapy.
  • Development of a stepwise strategy for risk management, encompassing screening, vaccination, family planning, adverse event management, and treatment optimization.

Main Results:

  • Six essential steps are identified to "derisk" anti-CD20 therapy.
  • Recommendations include pre-treatment screening and vaccination, upfront family planning discussions, proactive management of infusion reactions and adverse events, annual monitoring of immunoglobulin levels and vaccinations, and evidence-based retreatment strategies.

Conclusions:

  • Implementing these six steps can significantly improve the safety of anti-CD20 therapies.
  • A proactive and comprehensive approach is necessary to optimize the long-term use of anti-CD20 agents in neuroinflammatory diseases.